These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 20139893)

  • 1. Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment.
    Takeuchi M; Kimura S; Kuroda J; Ashihara E; Kawatani M; Osada H; Umezawa K; Yasui E; Imoto M; Tsuruo T; Yokota A; Tanaka R; Nagao R; Nakahata T; Fujiyama Y; Maekawa T
    Cell Death Differ; 2010 Jul; 17(7):1211-20. PubMed ID: 20139893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
    Hu Y; Chen Y; Douglas L; Li S
    Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
    Okabe S; Tauchi T; Ohyashiki K
    Clin Cancer Res; 2008 Oct; 14(19):6181-6. PubMed ID: 18829496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
    Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
    Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment.
    Stein AM; Bottino D; Modur V; Branford S; Kaeda J; Goldman JM; Hughes TP; Radich JP; Hochhaus A
    Clin Cancer Res; 2011 Nov; 17(21):6812-21. PubMed ID: 21903771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.
    Jiang X; Zhao Y; Smith C; Gasparetto M; Turhan A; Eaves A; Eaves C
    Leukemia; 2007 May; 21(5):926-35. PubMed ID: 17330101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
    Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
    Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
    O'Hare T; Walters DK; Stoffregen EP; Sherbenou DW; Heinrich MC; Deininger MW; Druker BJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6987-93. PubMed ID: 16203792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).
    La Rosée P; Corbin AS; Stoffregen EP; Deininger MW; Druker BJ
    Cancer Res; 2002 Dec; 62(24):7149-53. PubMed ID: 12499247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
    Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overriding imatinib resistance with a novel ABL kinase inhibitor.
    Shah NP; Tran C; Lee FY; Chen P; Norris D; Sawyers CL
    Science; 2004 Jul; 305(5682):399-401. PubMed ID: 15256671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
    Luo FR; Yang Z; Camuso A; Smykla R; McGlinchey K; Fager K; Flefleh C; Castaneda S; Inigo I; Kan D; Wen ML; Kramer R; Blackwood-Chirchir A; Lee FY
    Clin Cancer Res; 2006 Dec; 12(23):7180-6. PubMed ID: 17145844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
    Forster K; Obermeier A; Mitina O; Simon N; Warmuth M; Krause G; Hallek M
    Ann Hematol; 2008 Mar; 87(3):183-93. PubMed ID: 17960378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
    Kuroda J; Kimura S; Strasser A; Andreeff M; O'Reilly LA; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Tabe Y; Taniwaki M; Maekawa T
    Cell Death Differ; 2007 Sep; 14(9):1667-77. PubMed ID: 17510658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
    Puttini M; Coluccia AM; Boschelli F; Cleris L; Marchesi E; Donella-Deana A; Ahmed S; Redaelli S; Piazza R; Magistroni V; Andreoni F; Scapozza L; Formelli F; Gambacorti-Passerini C
    Cancer Res; 2006 Dec; 66(23):11314-22. PubMed ID: 17114238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.
    Valent P
    Br J Haematol; 2008 Jul; 142(3):361-78. PubMed ID: 18540942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.